--- title: "Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday" type: "News" locale: "en" url: "https://longbridge.com/en/news/278407493.md" description: "U.S. stocks fell sharply, with the Dow dropping 650 points. However, Relmada Therapeutics saw a significant rise of 40.8% to $6.27 after positive Phase 2 trial results for its cancer treatment. Other notable gainers included Hims & Hers (+42.6%), Xenon Pharmaceuticals (+42%), and Dianthus Therapeutics (+26.7%). United Therapeutics announced a $2 billion stock repurchase program, contributing to its 6.8% increase. Overall, several stocks experienced substantial gains despite the broader market decline." datetime: "2026-03-09T14:05:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278407493.md) - [en](https://longbridge.com/en/news/278407493.md) - [zh-HK](https://longbridge.com/zh-HK/news/278407493.md) --- # Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, with the Dow Jones index falling around 650 points on Monday. Shares of **Relmada Therapeutics Inc** (NASDAQ:RLMD) rose sharply during Monday's session following the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer. The 12-month interim data from the ongoing Phase 2 trial showed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population. Relmada Therapeutics shares jumped 40.8% to $6.27 on Monday. Here are some other big stocks recording gains in today’s session. - **Hims & Hers Health Inc** (NYSE:HIMS) shares jumped 42.6% to $22.44 after reports suggested that the company has agreed with Novo Nordisk to market weight-loss drugs from the Danish drugmaker on the Hims platform. Also, Novo Nordisk dropped its patent infringement case against the company. - **Xenon Pharmaceuticals In**c (NASDAQ:XENE) gained 42% to $59.53 following the announcement of positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures. - **W&T Offshore, Inc**. (NYSE:WTI) shares jumped 27.4% to $4.00. - **Dianthus Therapeutics In**c (NASDAQ:DNTH) gained 26.7% to $82.62 following an early GO decision announced by the company based on an interim responder analysis in the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). - **Uniqure NV** (NASDAQ:QURE) gained 21.1% to $17.28 after news that Dr. Vinay Prasad will step down from leading the U.S. Food and Drug Administration's biologics division. - **Solid Biosciences Inc** (NASDAQ:SLDB) shares rose 20% to $8.10. - **Regenxbio Inc** (NASDAQ:RGNX) shares jumped 18.7% to $10.26. - **Kingsoft Cloud Holdings Ltd** (NASDAQ:KC) shares climbed 14.3% to $13.70. - **Garden Stage Ltd** (NASDAQ:GSIW) shares climbed 10.2% to $10.51. - **Dyne Therapeutics Inc** (NASDAQ:DYN) gained 10.2% to $16.37. Dyne Therapeutics said it initiated Phase 3 HARMONIA trial of Zeleciment Basivarsen (Z-basivarsen, DYNE-101) For Myotonic Dystrophy Type 1. - **Lumentum Holdings Inc** (NASDAQ:LITE) gained 9.2% to $609.76. - **Circle Internet Group Inc** (NYSE:CRCL) gained 8.7% to $110.80. - **United Therapeutics Corp** (NASDAQ:UTHR) shares climbed 6.8% to $510.51. United Therapeutics announced a $2 billion stock repurchase authorization and enters into $1.5 billion accelerated share repurchase program. - **StubHub Holdings Inc** (NYSE:STUB) gained 6.7% to $8.92. - **Denali Therapeutics Inc** (NASDAQ:DNLI) shares surged 6.6% to $21.00. _Photo via Shutterstock_ ### Related Stocks - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md) - [XENE.US](https://longbridge.com/en/quote/XENE.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md) - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [RLMD.US](https://longbridge.com/en/quote/RLMD.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [How FDA RMAT Status For Bioengineered Liver Device At United Therapeutics (UTHR) Has Changed Its Investment Story](https://longbridge.com/en/news/282975066.md) - [Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares](https://longbridge.com/en/news/282414029.md) - [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md) - [BUZZ-Organon jumps on report of $12 bln buyout bid](https://longbridge.com/en/news/282320150.md) - [Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI](https://longbridge.com/en/news/282698267.md)